Skitii, the Mumbai-headquartered healthtech startup building AI solutions for cancer care, has raised fresh capital in a funding round that closed in mid-January 2026. While the exact amount remains undisclosed, the round was led by healthcare-specialised venture funds with participation from strategic angels who bring deep domain expertise in oncology and diagnostics. The investment will be used to scale the company’s proprietary AI platform, expand clinical partnerships, and accelerate regulatory and commercial milestones.

Skitii’s core technology integrates multimodal data radiology images, digital pathology slides, genomic profiles, electronic health records, and patient-reported outcomes into a unified AI engine that supports end-to-end cancer management. The platform provides clinicians with risk stratification scores, personalised treatment suggestions, therapy response prediction, and longitudinal monitoring capabilities. It is designed to assist oncologists in decision-making while remaining fully explainable and compliant with clinical standards.

Early pilots at leading cancer centres in Mumbai have demonstrated measurable impact: faster turnaround on complex cases, improved detection of actionable mutations, better therapy selection in precision oncology, and enhanced patient adherence through automated follow-up reminders. The company is now expanding its focus to common cancers in India breast, lung, oral, cervical, colorectal, and head & neck where early detection and consistent management can dramatically improve survival rates.

Co-founder and CEO Dr. Aarav Mehta said: “Cancer care in India suffers from delayed diagnosis, fragmented treatment, and limited access to precision tools in non-metro areas. Our AI platform bridges these gaps by bringing world-class decision support directly to oncologists at the point of care. This funding allows us to scale rapidly and reach the patients who need it most.”

The investment comes at a time when India’s oncology burden continues to rise, with over 1.4 million new cancer cases annually and significant regional disparities in access to advanced diagnostics and treatment. Skitii’s approach combining affordability, local-language interfaces, and offline-capable components makes it particularly well-suited for tier-2 and tier-3 cities where specialist availability remains limited.

The company plans to partner with hospital chains, diagnostic networks, and government initiatives under Ayushman Bharat to deploy its platform at scale. Regulatory filings for CDSCO approval and clinical validation studies are already underway, with first commercial rollouts targeted for late 2026.